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a b s t r a c t
The current antiretroviral therapy (ART) can effectively reduce plasma HIV loads to undetectable levels,
but cannot eliminate latently infected resting memory CD4 T cells that persist for the lifetime of infected
patients. Therefore, designing new therapeutic approaches to eliminate these latently infected cells or
the cells that produce HIV upon reactivation from latency is a priority in the ART era in order to progress
to a cure of HIV. Here, we show that “designer” T cells expressing chimeric antigen receptor (CAR),
CD4–CD28–CD3ζ, can target and kill HIV Env-expressing cells. Further, they secrete effector cytokines
upon contact with HIV Envþ target cells that can reactivate latent HIV in a cell line model, thereby
exposing those cells to recognition and killing by anti-HIV CARþ T cells. Taken to the limit, this process
could form the basis for an eventual functional or sterilizing cure for HIV in patients.
& 2013 Elsevier Inc. All rights reserved.
Introduction
The currently available ART used for the treatment of HIV patients
is highly effective in lowering plasma viral loads even to undetectable
levels (Gulick et al., 1997; Hammer et al., 1997; Luzuriaga et al., 1997).
However, apart from its toxicity during long-term use (Hawkins, 2010)
and high cost (Hill et al., 2011), it possesses a limitation in that it
cannot target or eliminate latent HIV residing in resting CD4 T cells in
patients (Chun et al., 1997; Finzi et al., 1999, 1997; Wong et al., 1997).
These latently infected cells are extremely stable and therefore persist
in vivo, even after prolonged suppressive therapy (Siliciano et al.,
2003), posing a major obstacle to HIV's cure by using ART. Soon after
therapy is withdrawn, viral loads return to pretreatment levels in most
patients (Davey et al., 1999; Garcia et al., 1999; Mata et al., 2005). To
achieve the complete eradication of HIV from patients, it is essential to
eliminate all HIV reservoirs (Bagasra et al., 1996; Lambotte et al., 2000;
Sonza et al., 2001; Zalar et al., 2010; Zhu et al., 2002), including latently
infected resting CD4 T cells, from the body. Since it became clear that
ART is unable to achieve this (Siliciano et al., 2003), new therapeutic
approaches are required to eliminate or control the pool of these HIV
reservoirs in patients.
In the ﬁeld of T cell immunotherapy, chimeric antigen receptors
(CARs) are created by directly linking viral or tumor antigen binding
domains of antibodies or ligands with the activating signaling domains
of CD3ζ or other receptors (Jena et al., 2010; Ma et al., 2002; Sadelain,
2009; Yang et al., 2007). The CAR-expressing T cells are often referred
as “designer T cells” (dTc). Previously, HIV Env-speciﬁc, chimeric
CD4–CD3ζ receptor-expressing dTc were found to efﬁciently target
and kill HIV-infected or HIV-Env expressing cells in vitro (Roberts et al.,
1994; Yang et al., 1997). In vivo, however, such a “1st generation”
construct was later tested in phase I and II clinical trials without
success (Deeks et al., 2002; Mitsuyasu et al., 2000;Walker et al., 2000).
Over the recent decade, there have been signiﬁcant advances in
our understanding of signaling requirements for effective T cell
function and an appreciation of the role of costimulation, e.g.,
through CD28 that provides a co-stimulatory signal important for
cell proliferation, cytokine production and cell survival (Beecham
et al., 2000; Boise et al., 1995; Emtage et al., 2008; Green et al.,
1995). Recently, we sought to apply these lessons in creating a
chimeric receptor of advanced design (2nd generation) that con-
sists of an extracellular CD4 domain attached with CD28 region,
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followed by the cytoplasmic effector domain of CD3ζ (namely,
CD4–CD28–CD3ζ), adding CD28 signaling to the 1st generation
format.
During the course of characterizing our newly designed CD4-
dTc product, we examined its effects on latently infected cells in
the ACH-2 cell line model of HIV latency. As expected, the CD4-dTc
could target and kill control HIV Envþ cells and HIV-infected H9
or primary T cells. However, to our surprise, with ACH-2 targets,
CD4-dTc cleared not only the small fraction (5–10%) of cells
making HIV in the total population of ACH-2 cells, but also nearly
eliminated the entire latent cell population. This clearance of
latently infected cells appeared to proceed in three steps:
(i) CD4-dTc were stimulated initially by small numbers of
HIV-expressing ACH-2 cells to release TNFα into the coculture
supernatants, (ii) locally released TNFα induced reactivation of
latent HIV in neighboring ACH-2 cells, and ﬁnally (iii) the newly
virus-expressing ACH-2 cells were targeted by the same CD4-dTc
population for elimination.
Results
Chimeric CD4–CD28–CD3ζ receptors
The designer T cells applied unsuccessfully in the prior clinical
trials mentioned above (Deeks et al., 2002; Walker et al., 2000)
possessed a CAR of the form CD4–CD3ζ, with CD4 extracellular
domain to engage gp120 on the surface of virus-infected cells and
CD3ζ cytoplasmically to activate T cell “Signal 1” for killing the
infected targets. The construct of our design possesses the trans-
membrane and partial extracellular domain of CD28 (Fig. 1A) that
mediates dimerization of chimeric molecules (Fig. 1B) and the
cytoplasmic domain that adds “Signal 2” co-stimulation to trans-
mit Signal 1þ2 on gp120 engagement. We refer to the modiﬁed T
cells with this new construct as 2nd generation dTc (i.e., CD4-dTc).
Cell surface expression of CD4–CD28–CD3ζ in human T cells.
Stimulated peripheral blood mononuclear cells (PBMCs)-
derived from normal donors were transduced with recombinant
retrovirus. To check the cell surface for CAR expression, cells were
double-stained with anti-CD4 and anti-CD8 antibodies and ana-
lyzed by ﬂow cytometry. The majority of CD8 T cells that were co-
stained with these antibodies represented CAR expressing cells,
estimated at 54% (Fig. 2B). Because CD4 antibodies used in these
stainings could not distinguish between natural versus engineered
CD4 molecules expressed on transduced CD4 T cells, myc staining
allowed us to judge the modiﬁcation of CD4 T cells. When
analyzed by staining with antibodies to myc-tag, a similar percen-
tage (53%) of transduced CD4 T cells was separately determined
(see Fig. 2D). Stimulated PBMCs were also modiﬁed with irrelevant
anti-carcinoembryonic antigen (αCEA) 2nd generation CAR
(Emtage et al., 2008) (Fig. 2F) for use as negative control dTc.
Cytotoxic effects of CD4-dTc on cells expressing HIV Env
To determine if CD4-dTc as effectors can kill target cells
expressing HIV Env, we cocultured equal numbers of CD4-dTc
and CEM-Envþ cells. In conventional short-term chromium-
release assays, we observed rates of 15–30% speciﬁc killing of
HIV Envþ targets over 5 h (not shown). To gain an impression of
the extent of killing that could be obtained, we examined 24–48 h
time periods using manual counting of target cells when
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Fig. 1. Schematic representations. (A) Retroviral vector and (B) cell-surface expres-
sion pattern of CD4–CD28–CD3ζ chimeric receptor. Ψ represents retroviral packa-
ging signal. EC, TM and CYT denote extracellular, transmembrane, and cytoplasmic
portions of the construct. A 10 amino acid Myc-tag is located at the N-terminus.
Fig. 2. Expression of CD4–CD28–CD3ζ in transduced PBMCs. Transduced and
control PBMCs were stained with antibodies (A and B: CD4 vs. CD8; C and D:
Myc vs. CD8) and analyzed by ﬂow cytometry. CD4-CAR-modiﬁed CD8 T cells in
panel B was 54%, after subtracting backgrounds observed in panel A that displays
naturally present double-positive CD4þCD8þ T cells. Myc staining in Panel D
shows 51% Mycþ CD8 T cells and 53% Mycþ CD4 T cells (CD8- cells), after
subtracting background myc-staining derived from C and non-T cells derived from
B. See Materials and Methods for calculations. Panels A, B, D pertain to a single
donor PBMC activation and transduction; panel C is from a different donor PBMC
activation to assess non-speciﬁc myc staining. Panel E and F represent unmodiﬁed
and modiﬁed PBMCs with anti-CEAscFv-CD28–CD3ζ construct, respectively. The
APC-labeled WI2 antibody reacted with the modiﬁed T cells that represent αCEA-
dTc. About 25% T cells were modiﬁed (for calculation, see materials and methods).
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chromium-release backgrounds would be too high (Emtage et al.,
2003; Junghans, 1990). As seen in Fig. 3A, the number of live CEM-
Envþ cells when cocultured with CD4-dTc was reduced 495% in
comparison to targets in control cocultures. These data establish
that CD4-dTc but not unmodiﬁed T cells preferentially target and
kill HIV Envþ cells in vitro.
A consequence of infected cell killing should be a reduced virus
production in culture. To test CD4–dTc for their ability to control HIV
replication in primary T cell cultures, we infected stimulated CD4 T
cells from normal donor with a CCR5-dependent virus strain, HIVJRCSF,
at moi 0.1 and cultured for 5 days. In the meantime, stimulated CD8
T cells from the same donor were transduced with CD4-CAR vector
and cultured for two days, and then incubated with the HIV-infected
CD4 T cells. As a surrogate for virus production, culture supernatants
were harvested and assayed for HIV-p24 levels by ELISA. As can be
seen in Fig. 3B, the rapid increases in p24 levels were observed to day
7 in infected CD4 T cell cultures, with or without control activated CD8
T cells (CD8/Tc) co-cultures. However, the level of p24 in the mixture
with gene-modiﬁed CD8 T cells (CD8/dTc) was 46-fold lower than in
control cultures. These data suggest that the gene-modiﬁed CD8 T cells
can control HIV replication and spread when mixed with infected
primary CD4 T cells (Fig. 3B), presumably by targeting and killing
speciﬁcally the infected cells in culture. The levels of p24 suppression
could not be explained by any non-speciﬁc cytolytic (Grimm et al.,
1982) or non-cytolytic suppressive effect (Rosok et al., 1997; Tsuchie
et al., 1997) caused by CD8/dTc, because no similar effect was seen
with CD8/Tc (Fig. 3B, middle).
To conﬁrm further the direct killing of HIV infected cells, CD4-dTc
were used to treat H9 T cell line infected with HIV213, a CXCR4-
dependent virus (Song et al., 1996), and then the cocultures were
evaluated by ﬂow cytometry. To distinguish the targets from the
effectors in the assay, 7-day infected H9 cells were labeled with
carboxyﬂuorescein succinimidyl ester (CFSE). When assayed by intra-
cellular staining with anti-p24 antibodies prior to mixing, these H9
cultures showed 490% infection (not shown). Then infected target
cells (i.e., H9/213 cells) were mixed with mock unmodiﬁed T cells (Tc)
or αCEA-dTc (Emtage et al., 2008) as controls (see Fig. 4A), or with
CD4-dTc at 1:1 ratio and incubated for 22 h at 37 1C. The αCEA-dTc
were T cells modiﬁed with αCEAscFv-CD28–CD3ζ (see Fig. 2F) that
could produce effector cytokines in response to CEA-expressing cells
and kill them (Emtage et al., 2008). The exogenous IL2 was not added
to media in these assays in order to reduce lymphokine activated killer
(LAK) activity of stimulated primary T cells (Grimm et al., 1982).
In parallel, equivalent numbers of effector and target cells were
cultured separately, and 22 h later they were mixed (served as 0 h
time point). Cell-mixtures were stained intracellularly with anti-HIV-
p24 antibody and evaluated by ﬂow cytometry. As can be seen in
Fig. 4A, H9/213 target cells were 96% reduced upon 22 h of coculture
with CD4-dTc (see right, 3rd panel from top), compared to control
cocultures with Tc or αCEA-dTc (top two panels on right). These data
demonstrated that the observed killing of target cells was due to the T
cells modiﬁed with CD4-CAR construct (i.e., CD4-dTc), but not because
of mere gene-modiﬁcation of these cells with any non-speciﬁc
construct by retroviral transduction. The cytotoxic effect of CD4-dTc
could be speciﬁcally reversed when these effectors were preincubated
with an HIV-blocking anti-human CD4 (domain I) antibody (20 mg/ml)
for 1 h (Fig. 4A, 2nd panel from bottom), demonstrating that interac-
tion between the CAR CD4 and HIV Env is crucial for CD4-dTc's
cytotoxicity towards HIV-infected target cells.
CD4 receptors are known to interact with HLA-DRmolecules, albeit
at much lower afﬁnity (Kd4100 mM) than with HIV Env (Kd6 nM)
(Gao et al., 2002; Lasky et al., 1987; Thali et al., 1991;Wang et al., 2001;
Weber and Karjalainen, 1993). Because H9 cells express HLA-DR
(Fig. 4C), we tested whether CD4-CAR/HLA-DR interaction contributed
to the CD4-dTc-mediated killing of target (H9/213) cells in Fig. 4A. Our
results showed no loss of cytotoxicity against infected H9/213 cells
with a blocking anti-HLA-DR antibody (Fu and Karr, 1994; Wang et al.,
1999) (Fig. 4A, 3rd panel from bottom). Further, CD4-dTc exhibited no
cytotoxicity towards HLA-DRþ uninfected H9 cells (Fig. 4B, lower
right). Finally, killing of CEM-Envþ cells, which are negative for HLA-
DR, is highly efﬁcient with the CD4-dTc, indicating no obligate role for
HLA class II in the killing and recognition of gp120þ targets. Overall,
these data rule out a role of HLA-DR/CD4-CAR interactions in the
observed killing of infected target cells by CD4-dTc.
During the 22 h incubation period, CD4 T cells in Tc or in αCEA-dTc
became infectedwith HIV produced by the H9/213 targets, as expected
(Fig. 4A, left upper quadrants). While a fraction of CD4 T cells or
CD4-CAR-modiﬁed CD8 T cells in CD4-dTc population would similarly
be infected, the CD4-dTc were able to perform self-targeting and
-killing for an in-vitro “self-cure” as reﬂected by the absence of p24þ
effectors after 22 h (Fig. 4A, compare upper left quadrants in top two
right panels with that in 3rd right panel from top).
In attempt to understand the mechanisms of CD4-dTc-mediated
killing of target cells, we used Concanamycin A (CMA) in our assays to
inhibit vacuolar type HþATPase important for perforin-based cytolytic
activity of CTLs (Emtage et al., 2003; Kataoka et al., 1996). CMA
partially suppressed the killing ability of CD4-dTc towards HIV infected
cells (from 96% to 68% killing; Fig. 4A), suggesting that the cytolytic
effector mechanisms of these CD4-dTc are at least partly mediated by
perforin, as noted with HIV-speciﬁc CTLs present in HIV controllers
(Hersperger et al., 2010; Saez-Cirion et al., 2009).
HIV-speciﬁc gene-modiﬁed T cell-mediated killing of a latently
infected cell line, ACH-2
Because HIV-Env expressing cells were found to be targeted
and killed by CD4-CAR modiﬁed T cells (as shown above), we
sought to examine their effects on ACH-2, a latently HIV infected,
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Fig. 3. Cytotoxic effect of gene-modiﬁed T cells (dTc) on target cells. (A) Target cell killing. Mock-transduced (Tc) or CD4-CAR-transduced (CD4-dTc) PBMCs were mixed with target
cells, CEM or CEM-Env, at 1:1 ratio and cultured for 2 days without exogenous IL2 in media. Live cells were counted on day 1 and day 2, and the values were normalized with the
corresponding target cells cultured alone, taken as 100%. The data pooled from two independent experiments performed in duplicate are shown. Asterisks (**) indicate po0.001.
(B) Viral titer suppression. HIVJRCSF-infected primary CD4 T cells were mixed with mock-transduced CD8 T cells (CD8/Tc) or CD4-CAR-transduced CD8 T cells (CD8/dTc) at 1:1 ratio
and cultured for 7 days. On days indicated, culture media were tested for HIV-p24 by ELISA (Advanced Bioscience Laboratories, Inc.). A representative data set from one of three
experiments is shown. Asterisks (nn) represent po0.03.
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transformed CEM cell line (Clouse et al., 1989; Folks et al., 1989).
Approximately 5% of these cells in culture express HIV constitu-
tively, whereas other 95% cells remain latent. We speculated that
the CD4-dTc would eliminate this positive cell fraction, while
sparing p24-negative cells with latent HIV.
We cocultured ACH-2 cells with CD4-dTc or Tc in 1:1 propor-
tion for 44 h. Unexpectedly, instead of eliminating only the small
5% virus expressing fraction of ACH-2 cells that we predicted, 85%
of ACH-2 cells were killed by CD4-dTc (Fig. 5, compare ovals in
bottom panels). By the preceding control tests, it is apparent that
this killing must have occurred in an antigen-speciﬁc manner, i.e.,
through CD4-CAR/HIV Env interaction. To explain this CD4-dTc-
speciﬁc lysis of latently infected ACH-2 cells, we speculated that
CD4-dTc somehow reactivated latent HIV in these cells, making
them targets for CD4-dTc-mediated killing in culture.
To investigate whether a soluble factor was mediating reactiva-
tion, fresh ACH-2 cells were incubated with coculture super-
natants and analyzed for p24 expression (Fig. 6A). When
incubated with fresh media or control culture supernatants,
ACH-2 cells were p24þ in the range of 7.5–11%. With supernatant
from ACH-2/CD4-dTc cocultures, ACH-2 was induced to 67% being
positive for p24-expression.
These data suggested that the interaction between low percent
virus-expressing ACH-2 cells (7.5%) and CD4-dTc might have
induced a factor in coculture supernatant that could reactivate
latent HIV in ACH-2 cells. We examined this hypothesis ﬁrst by
testing if CD4-dTc could produce various effector cytokines in
response to HIV-Envþ targets and controls (Table 1). We found
only CD4-dTc incubated with CEM-Envþ cells could produce IL2,
IFNγ and TNFα in culture, with all other cell combinations negative
for these cytokines.
It was previously reported that TNFα could reactivate latent HIV
in ACH-2 cells (Folks et al., 1989). To assay for a role for TNFα as
soluble inducer under our conditions, we pre-incubated varying
dilutions of coculture supernatant with TNFα neutralizing anti-
body prior to adding to ACH-2 cells. After overnight incubation, we
analyzed the percentage of HIVp24þ cells in culture by ﬂow
cytometry, and found that anti-TNFα antibody could suppress the
stimulatory effect of coculture supernatant on latent HIV in ACH-2
cells (Fig. 6B). This demonstrated that TNFα released from CD4-dTc
in coculture supernatants caused the reactivation of latent HIV in
ACH-2 cells, leading to their killing by CD4-dTc.
As a ﬁnal control, the ACH-2 cells' viability was not affected by
the secreted TNFα or other factors in these supernatants or by the
Fig. 4. dTc kill HIV-infected cells. (A) Speciﬁc CAR is required for dTc killing. CFSE-labeled H9/213 cells were mixed with Tc or αCEA-dTc or CD4-dTc at 1:1 ratio and incubated
for 22 h. Then cell-mixtures were stained intracellularly with anti-HIV-p24 antibody and analyzed by ﬂow cytometry. Bottom three panels show the effect of HIV-blocking
anti-human CD4 antibody or anti-human HLA-DR antibody or Concanamycin A (CMA) (see Materials and methods). Raw counts of p24þ H9 cells are represented in upper
right quadrants for control and experimental samples at 22 h. Percent speciﬁc lysis expressed in terms of target cell loss was calculated as described in Materials and
methods. (B) Lack of killing of uninfected DRþ H9 cells by CD4-dTc. CFSE-labeled H9 cells were mixed with Tc or CD4-dTc at 1:1 and incubated for 22 h and analyzed by ﬂow
cytometry as in A. Numbers shown in lower right quadrants represent raw counts of H9 cells at 22 h. (C) Expression of HLA-DR on various cells. Cells were stained with anti-
human HLA-DR antibody or matched isotype control antibody and analyzed by ﬂow cytometry. The stainings with isotype control antibody are shown by histograms to the
left (top panels) or as overlapped with αHLA-DR staining (bottom panels). Stimulated PBMCs cultured for two weeks in media with 300 U/ml IL-2 before staining with
antibody.
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re-expressed HIV, even after 44 h of incubation (Fig. 6C). Hence,
the extensive killing of ACH-2 cells shown in Fig. 5 required the
presence of CD4-dTc cell fraction in cocultures. That is, the two
functions of reactivating latent HIV in ACH-2 cells followed by the
killing of virus expressing cells were each separately mediated
activities of CD4-dTc.
Discussion
The HIV-speciﬁc, cytotoxic designer T cells of this study can
recognize and kill HIV envelope expressing cells in an MHC-
independent fashion, whereas natural CTLs in vivo require MHC-I
dependent antigen presentation on the surface of infected cells for
recognition and killing. The cytotoxicity of HIV-speciﬁc CD4-dTc
requires CD3ζ linked to CD4 molecules C-terminally, either directly
or through a domain of other molecules, in this case, costimulatory
Fig. 5. CD4-dTc kill latently infected cells. Equal numbers of ACH-2 cells were mixed
with at least two wks grown Tc or dTc at 1:1 ratio and incubated for 44 h. The cell
mixtures were stained at 0 h and 44 h with antibodies to CD4, CD8 and intracellularly
expressed HIV-p24 antigens, followed by ﬂow cytometry. The stained CD4 and CD8 T
cells clustered together in ﬂow diagrams, whereas ACH-2 cells clustered separately
(oval) as they are negative for both CD4 and CD8 expression. The horizontal line
indicates the cut-off for p24 expression. Raw counts of total ACH-2 cells for control and
experimental cultures at 44 h are shown above ovals. Percent speciﬁc killing of ACH-2
cells by CD4-dTc was calculated as in Materials and methods.
Fig. 6. Reactivation of latent HIV during CD4-dTc stimulation by target cells. (A) Supernatants from cocultures reactivate latent HIV in ACH-2 cells. Supernatants were
collected from 24 h co-cultures of effector and various target cells mixed at 1:1 ratio. ACH-2 cells were incubated with the coculture supernatants for 24 h and assayed for
HIV-p24 expression by intracellular staining and ﬂow cytometry. (B) TNFα neutralization inhibits latent HIV reactivation in ACH-2 cells. Supernatants harvested from ACH-2
and CD4-dTc coculture were incubated at different dilutions with or without TNF-α antibody (5 mg/ml) at 37 1C for 1 h, and then added to ACH-2 cells for 18 h, followed by
detection of p24þ cells in ﬂow cytometry as in A. (C) ACH-2 cells' viability after latent HIV reactivation. Coculture supernatant from ACH-2 and CD4-dTc were added to fresh
ACH-2 cells and incubated for 44 h at 37 1C. Upper panels: Potent reactivation of latent HIV occurred by coculture supernatant (right) compared to untreated control (mock)
(left). Lower panels: Scatter plots were analyzed for viable (R2) versus dead (R1) cells before (left) and after (right) treatment.
Table 1
Production of effector cytokines in gene-modiﬁed T cells upon engagement with
HIV-gp160.
Mixtures of effector
and target cells
Levels of cytokines or effector
molecules (in pg/ml)
IL2 TNFα IFNγ
CEMþTc o4 o4 o4
CEMþCD4-dTc o4 o4 o4
CEM-EnvþTc o4 o4 o4
CEM-EnvþCD4-dTc 31876 249746 8387169
7 , SD. These data are representative of 3 independent experiments.
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domain of CD28. The modiﬁcation of CTLs by CD4 alone without
attached signaling domains would not be expected to mediate
cytotoxic effects against HIVþ cells, as previously reported with
various constructs (Finney et al., 2004; Haynes et al., 2002).
Further, the cytolytic activity of CD4-CAR expressing dTc towards
HIV infected cells requires the high afﬁnity interaction between
CD4-CAR and HIV Env (Lasky et al., 1987; Thali et al., 1991) that is
not duplicated with a low afﬁnity interaction between CD4-CAR
and MHC-II (Gao et al., 2002; Wang et al., 2001; Weber and
Karjalainen, 1993).
HIV can down-modulate MHC-I molecules in infected cells
(Peterlin and Trono, 2003), which serves as one of the immune
evasive mechanisms for HIV (Yewdell and Hill, 2002). However,
such down-modulation would not abrogate the recognition of
infected cells by HIV-speciﬁc designer T cells. Thus, there could be
a potential utility of these gene-modiﬁed T cells in vivo in the post-
ART era, for example, infusion of CD4-dTc into patients on ART
could result in targeting of persistently active HIV reservoirs (Chun
et al., 2008; Poles et al., 2006), reducing or eliminating their pool
in the body.
The ACH-2 cell line has been applied as a model for HIV latency,
with 90–98% of the cells expressing no virus although harboring
HIV provirus. Unexpectedly, most ACH-2 cells were found to be
attacked and killed in vitro by our HIV-speciﬁc CD4-dTc rather
than just the minor HIV-expressing fraction. This outcome was
attributed to induction of HIV expression in latent cells by locally
secreted TNFα from CD4-dTc responding to the small percent of
HIV-expressing ACH-2 cells. Although it was previously reported
that TNFα can reactivate these latent cells (Folks et al., 1989), it was
uncertain prior to this study whether TNFα could be produced at
sufﬁcient levels by CD4-dTc engaging with small numbers of
reactive targets, so that it can reactivate nearby latent targets.
Yet it is unclear whether such scenario will also apply to in vivo
where patients are infused with these designer T cells. In in-vitro
models of HIV latency that employ primary CD4 T cells, TNFα by
itself is unable to reactivate latent HIV (Bosque and Planelles,
2009; Tyagi et al., 2010). TNFα has the property of inducing NF-kB
activation and nuclear translocation, which is sufﬁcient for reacti-
vating latent virus in ACH-2 cells. In contrast, the latently infected
quiescent CD4 T cells in the primary cell model additionally
require activated pTEF-b complex for viral emergence (Tyagi
et al., 2010), because this complex is nearly absent in primary
cells (Herrmann et al., 1998). Thus, the CD4-dTc are able to deliver
the one of two important “signals” for latent HIV reactivation; if
means are discovered to selectively activate pTEF-b as the other
“signal”, by pharmacological means or as a component of dTc
engineering, then an opportunity for a progressive spreading of
latent HIV reactivation and elimination can be envisioned that
could deplete latent reservoirs in patients.
Alternatively, the HIV-speciﬁc designer T cells, if remaining
active and engaging in immune surveillance in infused patients,
could target and kill latently infected cells that re-express HIV, as
shown in this report. Such a scenario could lead to sustained
control of viremia at clinically undetectable levels, even after ART
withdrawal, and suggests the possibility of a ‘functional cure’
for HIV.
Materials and methods
Retroviral vectors, cell lines, plasmids, and antibodies
A retroviral vector with MFG vector backbone expressing anti-
CEA-scFV-CD28–CD3ζ was used (Emtage et al., 2008) to generate
recombinant plasmids for the study. Phoenix amphotropic and
ecotropic cells and murine helper cell line, PG13, were purchased
from American Type Culture Collection (ATCC), USA. A clonal T cell
line (CEM-Env) expressing HIV Env at the cell surface and a virus
strain, HIV213 were the gifts from Dr. Miles Cloyd, University of
Texas Medical Branch at Galveston.
A DNA fragment for the expression of extracellular portion of
human CD4 molecule with myc epitope tag at the N-terminus was
generated and ligated into the vector as shown in Fig. 1A to
express chimeric CD4–CD28–CD3ζ protein in transduced cells
(Fig. 1B). The pseudotyped retroviral vector was produced and
used to transduce stimulated T cells (see below).
The following antibodies reactive to human target molecules
were used: Anti-CD4, -CD8 antibodies conjugated to PE (phycoer-
ythrin), APC (allophycocyanin) and FITC (ﬂuorescein isothiocya-
nate) antibodies were purchased from eBioscience. The anti-
HIVp24-PE, anti-Myc-FITC, HIV-blocking anti-CD4 antibody (clone
QS4120) and anti-human HLA-DR antibody (clone G46-6[L243])
were purchased from Coulter, Sigma, Ancell Corporation, and BD
Biosciences, respectively. The APC-labeled WI2, an anti-idiotype
antibody to anti-CEAscFv (αCEA) were obtained from Immunome-
dics (Emtage et al., 2008).
Preparation of a stable cell line expressing recombinant retrovirus
with CAR-cassette
The retroviral construct (plasmid) encoding 2nd generation
chimeric CD4–CD28-zeta molecule (see Fig. 1A) was used to
transfect a mixture of Phoenix ampho- and eco-tropic cells (ATCC,
USA) as previously described (Beaudoin et al., 2008). Twenty-four
hours later, the transduced Phoenix-mix cells expressing chimeric
protein were sorted once. The culture supernatant from the sorted
virus-producing cells was used to transduce a PG13 (empty)
murine helper cell line for stable integration and virus particle
production. The PG13 cells express gibbon ape leukemia virus
(GaLV) envelope, in addition to murine leukemia virus gag-pol
proteins, for pseudotyping the recombinant retroviral vector. The
human cells, in contrast to mouse cells, can be infected readily
with these pseudotyped retroviruses (Miller et al., 1991). The
transduced cells that express 2nd generation chimera at the cell
surface were identiﬁed by staining with antihuman CD4 antibo-
dies (eBioscience, USA), followed by ﬂow cytometry. The antibody
stained CD4þ PG13 cells were sorted by ﬂuorescence activated
cell sorter (FACS) and expanded in culture. This stable line was
used as the source of retrovirus particles that are cable of
expressing CD4-CAR (i.e., CD4–CD28–CD3ζ chimera) upon trans-
duction into human T cells.
Transduction of human PBMCs with recombinant retrovirus and
culture
PBMCs were isolated from normal donor's blood by ﬁcoll-
hypaque method, and stimulated with anti-CD3ε antibody (clone
OKT3) at 100 ng/ml concentration in RPMI media, 10% fetal bovine
serum for two days. Then stimulated PBMCs were cultured in
presence of 300 IU/ml IL2 for another 2 days. For transduction,
8106 cells were mixed with 3 ml of culture supernatant
harvested from vector producing cells in 6-well plate coated with
retronectin (10 mg/ml, Takara) and centrifuged for 2 h at 32 1C.
After overnight incubation at 37 1C in CO2 incubator, culture
supernatants were removed and cells were transduced for the
second time to increase transduction efﬁciency. Next day, super-
natants were replaced with fresh media containing 300 U/ml IL2
and cells were maintained in culture for 2–3 weeks in presence of
IL2 (100 IU/ml). Within this time period, portions of cells were
harvested and used in various experiments.
To determine the percentage of gene-modiﬁed T cells in culture
in Fig. 2, (A) mock and (B) transduced cells were stained using
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anti-CD8-APC and anti-CD4-PE antibodies or, (C) mock and
(D) transduced cells were stained with anti-CD8-APC and anti-
Myc-FITC antibody and analyzed by ﬂow cytometry.
In Fig. 2B, the formula used to calculate the modiﬁed CD8 cells
was: %Ttransduced¼100Q2/(Q2þQ4). The fraction of double-positive
cells (CD4þCD8þ) naturally present at baseline in Fig. 2A (Q2: 2.8%)
was subtracted from Q2 in numerator and denominator because these
cells could not be judged for modiﬁcation.
In Fig. 2D, the formula used to calculate the modiﬁed CD8 T
cells was: %Ttransduced¼100Q2/(Q2þQ4), in which background
myc staining from (C) (Q2: 0.9%) was subtracted from Q2 in
numerator and denominator. We examine the CD8- population
to infer the fraction of CD4 cells. The formula to calculate modiﬁed
CD4 T cells was: %Ttransduced¼100Q1/(Q1þQ3) in which back-
ground myc staining from (C) (Q1: 0.7%) was subtracted from Q1
in numerator and denominator. In addition, the fraction of non-T
cells (CD4–CD8-) from PBMC that are present in the transduction
from (B) (Q3: 9.1%) is subtracted from Q3 in D in estimating the
unmodiﬁed CD4þ T cells in the denominator. This fraction is seen
as 9.7% in Fig. 2A and 9.1% in Fig. 2B, essentially unchanged by the
transduction. Non-dividing non-T cells would not be expected to
be modiﬁed.
dTc killing assay by ﬂow cytometry
Speciﬁc killing of various HIV-infected target cells by dTc was
also determined by ﬂow cytometric analysis. Effector and target
cells were mixed at 1:1 ratio in equal volumes in 48-well plate and
incubated for speciﬁed times. Using changes in cell percents in the
mixtures per usual practice cannot be applied if the total cells in
the analysis change due to target cell killing. Instead, the same
proportion of the sample is counted and the numbers of targets in
that portion is representative of the surviving fraction. To achieve
this, total samples were thoroughly collected, processed equiva-
lently and resuspended in equal volumes for ﬂow cytometric
analyses. To allow for different total counts due to target killing
in some samples, each sample was analyzed for an identical ﬁxed
time (e.g., 20 s). Because the ﬂow setting is in microliters
per second, this ensures the same sample volume is processed
and counted. To determine the speciﬁc killing due to dTc, the
target cell counts in control cultures with activated non-
transduced T cells (Tc) were taken as 100% and then target cell
counts in dTc coculture were normalized accordingly. The percent
speciﬁc lysis (%SL) of HIV-infected target cells due to dTc was
calculated by using a formula: %SL¼100 (1(surviving targets
with dTc/surviving targets with Tc). Killing is expressed as a
negative number in ﬁgures to emphasize the loss of cells as
opposed to a positive measure of lysis such as chromium-release.
Carboxyﬂuorescein succinimidyl ester (CFSE) labeling and HIV-p24
antibody staining
These were done by following the previously published meth-
ods (Lyons and Parish, 1994; Sahu et al., 2006).
Treatment of effectors (CD4-dTc) with various antibodies or
Concanamycin A prior to mixing with target cells, whenever required
To examine the blocking effects of various reagents in our
killing assays, effectors (CD4-dTc) were incubated with HIV-
blocking anti-human CD4 (domain I) antibody (20 mg/ml) or
anti-human HLA-DR antibody (10 mg/ml) or Concanamycin A
(160 nM, Sigma) at 37 1C for 1 h prior to mixing and incubation
with infected (H9/213) cells for 22 h, followed by intracellular
staining and ﬂow cytometry.
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